The launch of emerging therapies such as Budesonide Oral Suspension, Dupilumab, Cendakimab, APT-1011, and others during the forecasted period 2021-2030 is predicted to boost the dynamics of the Eosinophilic Esophagitis market
LAS VEGAS, May 6, 2021 /PRNewswire/ -- DelveInsight's "Eosinophilic Esophagitis (EoE) Market" report provides a thorough comprehension of the Eosinophilic Esophagitis, historical and forecasted epidemiology, and the Eosinophilic Esophagitis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Eosinophilic Esophagitis market report also proffers an analysis of the current Eosinophilic Esophagitis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the imperative takeaways of the Eosinophilic Esophagitis Market Research Report
- A slew of companies such as EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline, Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, and others are developing therapies to influence Eosinophilic Esophagitis treatment outlook.
- Increased understanding of the clinical manifestations of the disease in conjunction with improved diagnosis and evolving treatment landscape will boost the Eosinophilic Esophagitis market landscape scenario..
- The US FDA has granted priority review, breakthrough therapy designation, and orphan designation to Budesonide Oral Suspension (BOS) for the EoE treatment.
- In the Phase II study, RPC4046 demonstrated positive results. Currently, Bristol-Myers Squibb is conducting a Phase III clinical study to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with the indication.
- APT-1011 has received orphan drug designation from the FDA. It is currently in Phase III development (FLUTE II), following the successful completion of its phase II study (FLUTE I) in 2019.
- Benralizumab is currently approved under the brand name Fasenra as an add-on maintenance treatment of severe asthma in patients aged =12 years and with an eosinophilic phenotype. Now, it is being evaluated in the Phase III study for the treatment of EoE.
- Currently, Lirentelimab is being evaluated in Phase II/III study for the Eosinophilic Esophagitis treatment in adult and adolescent subjects. The US FDA has granted orphan drug designation to antolimab for the treatment of EoE.
For further information on Market Impact by Therapies, visit: Eosinophilic Esophagitis Drug Market Analysis
Eosinophilic Esophagitis (EoE) represents a chronic, local immune-mediated oesophagal disease, characterized clinically by symptoms related to oesophagal dysfunction and histologically by eosinophil-predominant inflammation.
As per the estimates by DelveInsight, the total diagnosed Eosinophilic Esophagitis prevalent cases in 2020 were 547,924 cases. The highest prevalent cases were observed in the United States, accounting for approximately 58% of the total cases.
The Eosinophilic Esophagitis Market Report provides historical as well as forecasted epidemiological analysis segmented into:
- Diagnosed Eosinophilic Esophagitis Prevalence
- Gender-specific Eosinophilic Esophagitis Cases
- Age-specific Eosinophilic Esophagitis Cases
Get a sample copy of this report: Eosinophilic Esophagitis Market Size Landscape
Eosinophilic Esophagitis Treatment Market
The Eosinophilic Esophagitis treatment involves Drugs, Diet, and Dilation. The first two components, which involve the use of proton pump inhibitors (PPIs), corticosteroids, immunosuppressant's, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases. In contrast, endoscopic dilation is reserved for oesophagal strictures.
Three dietary approaches for the management of EoE have emerged: the elemental diet, empiric dietary restrictions, and targeted dietary restrictions based on allergy testing.
PPIs are helpful as a first-line treatment for EoE patients. This therapy reduces acid production in the stomach and can reduce oesophagal inflammation. PPIs are recommended to be administered twice daily and continued for a minimum 2-month course after oesophagal eosinophilia is discovered. Afterwards, a repeat endoscopy with biopsies is performed to assess for persistent eosinophilic infiltration.
Corticosteroids, which control inflammation, are another effective therapy for the treatment of EoE. By swallowing small doses of corticosteroids, they contact and treat the inner lining of the oesophagus. Different forms of swallowed corticosteroids are available. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission.
Oesophagal endoscopic dilation is most commonly used in adults with established oesophagal strictures. Although many physicians are fearful of dilating Eosinophilic Esophagitis patients due to concerns regarding mucosal tears and perforations, numerous case series attest to the safety and efficacy of oesophagal dilation.
The Food and Drug Administration currently approves no drugs for the EoE treatment. However, off-label medications have also been shown to reduce the number of eosinophils in the oesophagus and improve symptoms.
Eosinophilic Esophagitis Emerging Therapies Along with Key Players
- Budesonide Oral Suspension: Takeda
- Dupilumab: Regeneron Pharmaceuticals/Sanofi
- Cendakimab: Bristol-Myers Squibb
- APT-1011: Ellodi Pharmaceuticals
- Benralizumab: AstraZeneca
- Lirentelimab: Allakos
And several others.
Final thoughts on Eosinophilic Esophagitis Market Growth
Eosinophilic Esophagitis Market Drivers such as increasing awareness, the emergence of non-invasive modalities, identification of biomarkers, development of animal models are responsible for Market Growth. In contrast, Eosinophilic Esophagitis Market Barriers such as high cost of treatment, lack of multidisciplinary management, and lack of optimal endpoint for treatment will nosedive the market size.
Scope of the Eosinophilic Esophagitis Market Insight Report
- Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
- Eosinophilic Esophagitis Markets Segmentation: By Geographies and By Eosinophilic Esophagitis Therapies (Historical and Forecasted, Current and Upcoming)
- Dominant Market Companies investigating its candidates for Eosinophilic Esophagitis: EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline, Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, and several others.
- Analysis: Comparative and conjoint analysis of emerging therapies.
- Case Studies
- KOL's Views
- Analyst's View
Request for a Webex demo of the report @ Eosinophilic Esophagitis Treatment Market Size
Table of Contents
1 | Eosinophilic Esophagitis (EoE) Key Insights |
2 | Eosinophilic Esophagitis Report Introduction |
3 | Eosinophilic Esophagitis Market Overview at a Glance |
4 | Eosinophilic Esophagitis Patient Split at a Glance |
5 | Executive Summary of Eosinophilic Esophagitis |
6 | Eosinophilic Esophagitis Disease Background and Overview |
7 | EoE Treatment |
8 | Guidelines for Management of EoE |
9 | Eosinophilic Esophagitis Epidemiology and Patient Population |
9.1 | The United States |
9.2 | EU5 Countries |
9.2.1 | Germany |
9.2.2 | France |
9.2.3 | Italy |
9.2.4 | Spain |
9.2.5 | The United Kingdom |
9.3 | Japan |
10 | Organizations contributing toward the fight against EoE |
11 | EoE Patient Journey |
12 | Case Report |
13 | Eosinophilic Esophagitis Marketed Drug |
13.1 | Jorveza: Dr Falk Pharma GmbH |
14 | Eosinophilic Esophagitis Emerging Drugs |
14.1 | Budesonide Oral Suspension: Takeda |
14.2 | Dupilumab: Regeneron Pharmaceuticals/Sanofi |
14.3 | Cendakimab: Bristol-Myers Squibb |
14.4 | APT-1011: Ellodi Pharmaceuticals |
14.5 | Benralizumab: AstraZeneca |
14.6 | Lirentelimab: Allakos |
15 | Other Promising Therapies |
15.1 | ESO-101: EsoCap AG |
15.2 | Etrasimod: Arena Pharmaceutical |
15.3 | Mepolizumab: GlaxoSmithKline |
16 | 7MM Eosinophilic Esophagitis Market Analysis |
16.1 | The United States Eosinophilic Esophagitis Market Size |
16.2 | EU-5 Eosinophilic Esophagitis Market Size |
16.2.1 | Germany Market Size |
16.2.2 | France Market Size |
16.2.3 | Italy Market Size |
16.2.4 | Spain Market Size |
16.2.5 | The United Kingdom Market Size |
16.3 | Japan Eosinophilic Esophagitis Market Size |
17 | KOL Views |
18 | Eosinophilic Esophagitis Market Drivers |
19 | Eosinophilic Esophagitis Market Barriers |
20 | SWOT Analysis of Eosinophilic Esophagitis |
21 | Eosinophilic Esophagitis Unmet Needs |
22 | Appendix |
23 | DelveInsight Capabilities |
24 | Disclaimer |
25 | About DelveInsight |
Browse full report with detailed TOC with charts, figures, tables @ Eosinophilic Esophagitis Market Share Report
View Related Reports
- Eosinophilic Esophagitis Epidemiology Forecast
DelveInsight's Eosinophilic Esophagitis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Eosinophilic Esophagitis.
- Eosinophilic Esophagitis Pipeline
Eosinophilic Esophagitis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Eosinophilic Esophagitis market.
- Erosive Esophagitis Market
DelveInsight's Erosive Esophagitis (EE) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology of Eosinophilic Esophagitis.
- Esophageal Cancer Market
DelveInsight's Esophageal Cancer - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
- Radiation-induced Esophagitis Market
DelveInsight's Radiation-induced Esophagitis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a depth understanding of historical and forecasted epidemiology.
- Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) Market
DelveInsight's 'Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease historical & forecasted epidemiology, as well as the market trends of GEJ-NET in the 7MM.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
